Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock on August 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold shares of common stock on August 20, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• Tanimoto sold shares directly and indirectly through the Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020, and the Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006.
• The weighted average sale prices ranged from $14.7565 to $16.2589 per share.
• Following the transactions, Tanimoto directly owns 3,407,847 shares and indirectly owns shares through various trusts, including 1,497,447 shares via the Sarina Tanimoto Charitable Remainder UniTrust and 1,498,499 via the Lowenthal-Tanimoto Family Trust.
• She also indirectly owns 1,446,494 shares via the Richard E. Lowenthal Charitable Remainder UniTrust and 4,315,313 shares via her spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, which doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's perspective on the company's prospects. Sales under a 10b5-1 plan are generally viewed as less informative since they are pre-arranged.

Stakeholder Impact

• The stock sales by a key executive could be perceived negatively by some shareholders, potentially leading to short-term price fluctuations.
• However, the existence of a 10b5-1 plan mitigates concerns about insider information being used for personal gain.

Key Dates